Idelalisib — A PI3Kδ Inhibitor for B-Cell Cancers
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The phosphoinositide 3-kinase (PI3K) signal transduction pathway is highly active in tumors and drives many of the hallmarks of cancer. Efforts to develop PI3K inhibitors for oncology have been complicated by the existence of four distinct PI3K catalytic isoforms with partially overlapping functions. In addition, diverse resistance mechanisms and on-target toxic effects have been observed with many PI3K inhibitors.1,2 In this issue of the Journal, two clinical teams report that idelalisib, a selective inhibitor of the delta isoform of PI3K, provides impressive efficacy and has an acceptable side-effect profile when used to treat patients with certain B-cell cancers.3, . . .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Klempner, S. J., Myers, A. P., & Cantley, L. C. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0063 · Cited by 148
Self-citation
Cited by
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
“…of other BCR signaling components causes similar B-cell phenotypes in mice, and germline mutations cause agammaglobulinemia in humans (Fruman et al., 2000b; Deane and Fruman, 2004). p110d and BTK also function in shared signaling pathways in human B-cell tumors (Fruman and Cantley, 2014).”
BackgroundSelf-citationPI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Thorpe, L. M., Yuzugullu, H., & Zhao, J. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3860 · Cited by 1,345
PI3K signalling in inflammation
Hawkins, P. T., & Stephens, L. R. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.12.006 · Cited by 541
Understanding phosphoinositides: rare, dynamic, and essential membrane phospholipids
Dickson, E. J., & Hille, B. (2019) · Biochemical Journal · doi:10.1042/bcj20180022 · Cited by 254
Huang, Y., Liu, N., Liu, J., Liu, Y., Zhang, C., Long, S., Luo, G., Zhang, L., & Zhang, Y. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1688951 · Cited by 94
Metadata
- Authors
- Fruman, D. A., & Cantley, L. C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-03-13
- Volume
- 370
- Issue
- 11
- Pages
- 1061-1062
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2072528662
- Cited by
- 99
- References
- 1
- FWCI
- 5.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.